Back to School: How biopharma can reboot drug development. Access exclusive analysis here

IntraVec: The higher education of cells

IntraVec Inc. foresees therapeutic solutions for cancer and infectious diseases that would eliminate surgery, recurrent drug and vaccine administrations, chemotherapy and radiation - interventions that often require protracted treatments and which IntraVec considers to have limited utility in remediating chronic disease.

The company, which is developing three genetic engineering therapeutic platforms and a gene screening process, started last August with seed capital from Wake Forest University and is operating as an incubator company under the auspices of university technology transfer company QED Technologies Ltd.

Read the full 837 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE